Jim Banting

Jim Banting

Directeur Général chez PARTEQ Innovations

Health Technology
Consumer Services
Finance

Profil

Dr. Jim Banting is President & Chief Executive Officer at PARTEQ Innovations.
Prior to joining PARTEQ Innovations, Dr. Banting was employed as Head of Business Development by Sigma-Tau Pharmaceuticals, Inc., a U.S.
company focused on rare diseases.
Previously, he spent six years in the business development group of the U.S.
biotechnology company Human Genome Sciences.
In that role, he led the due diligence and negotiation of a number of in- and out-licensing, manufacturing, platform, and co-development related collaborations.
He has also worked at the proteomics company Caprion, securing numerous biomarker discovery collaborations with industry partners.
His career began as a co-founder of the Queen's spin-off company Vaxis Therapeutics that was funded by venture capitalists.
After growing the company, Dr. Banting served as the business development lead on the sale of Vaxis to a U.S.
specialty pharmaceutical company.
Dr. Banting graduated from Queen's in 1993 with an honours degree in Life Sciences.
He earned his doctorate in pharmacology at Queen's.

Postes actifs de Jim Banting

SociétésPosteDébut
Directeur Général -
Tous les postes actifs de Jim Banting

Anciens postes connus de Jim Banting

SociétésPosteFin
Corporate Officer/Principal -
Corporate Officer/Principal -
Corporate Officer/Principal -
Voir l'expérience en détail de Jim Banting

Formation de Jim Banting

Queen's University Undergraduate Degree

Expériences
Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Voir l'expérience en détail de Jim Banting

Relations

100 +

Relations au 1er degré

5

Entreprises liées au 1er degré

Homme

Femme

Administrateurs

Exécutifs

Voir le réseau personnel

Sociétés liées

Entreprise privées4

Health Technology

Health Technology

Health Technology

Finance

Voir les connexions sociétés
  1. Bourse
  2. Insiders
  3. Jim Banting